4142:TPE
Adimmune Corp
16,15 TWD
arrow_downward
−0,62%(−0,10) 1 D
18. nov., 13:30:02 GMT+8 · TWD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for 4142 …
Åpne
16,35 TWD
Høy
16,55 TWD
Lav
16,00 TWD
Markedsverdi
6,94 mrd.
Snittvolum
1,09 mill.
Volum
534,85k
52 u høy
21,50 TWD
52 u lav
15,65 TWD
EPS
−0,34 TWD
Utestående aksjer
235,29 mill.
Antall ansatte
564
Åpne
16,35 TWD
Høy
16,55 TWD
Lav
16,00 TWD
Markedsverdi
6,94 mrd.
Snittvolum
1,09 mill.
Volum
534,85k
52 u høy
21,50 TWD
52 u lav
15,65 TWD
EPS
−0,34 TWD
Utestående aksjer
235,29 mill.
Antall ansatte
564
Nyhetssaker
Fra nettkilder og nyhetspartnere
BeInCrypto
·
for 1 time siden
How Deep Do S&P 500 Corrections Usually Go? Where 2026’s Drop Ranks
The Motley Fool
·
for 58 minutter siden
Vanguard S&P 500 ETF vs. Schwab U.S. Dividend ETF: How Much You’d Need to Collect $1,000 a Month From Each.
MarketWatch
·
for 2 timer siden
Stock Market Today: Dow, S&P 500 and Nasdaq set to climb as Nvidia shares rise after boosting guidance; Anthropic expected to price IPO: live updates
BigGo Finance
·
for 13 timer siden
Wall Street Split on 2027 S&P 500 Outlook: Wells Fargo's 8,200 vs. Morgan Stanley's 8,700
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Om Adimmune Corp
Administrerende direktør-
Ansatte564
Grunnlagt1965
Hovedkontor-
SektorHealth Care
Bransje-
Nettstedadimmune.com.tw